comparemela.com

Latest Breaking News On - Authorisation application - Page 5 : comparemela.com

ICCC grants clearance to Santos – EMTV Online

ICCC grants clearance to Santos – EMTV Online
emtv.com.pg - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from emtv.com.pg Daily Mail and Mail on Sunday newspapers.

Oil-search-limited
Competition-commission
Oil-search
Santos-limited
Independent-consumer
Authorisation-application
Paulus-ain
Proposed-acquisition

Orphazyme provides regulatory update following Type A

Orphazyme A/SCompany announcement        No. 24/2021Inside informationCompany Registration No. 32266355 Progress made in understanding potential.

United-states
Denmark
Copenhagen
Køavn
Switzerland
Christophe-bourdon
Anders-vadsholt
Drug-administration
Exchange-commission
Company-annual-report-on-form
European-medicines-agency
Company-registration-no

F. Hoffmann-La Roche Ltd: FDA accepts application for Roche's Port Delivery System with ranibizumab (PDS) for treatment of neovascular or wet age-related macular degeneration (nAMD)

F. Hoffmann-La Roche Ltd: FDA accepts application for Roche's Port Delivery System with ranibizumab (PDS) for treatment of neovascular or wet age-related macular degeneration (nAMD)
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Japan
Ireland
United-states
United-kingdom
Switzerland
America
Irish
American
British
Nathalie-meetz
Levi-garraway
Jon-kaspar-bayard

Amryt Reports Record Q1 2021 Financial and Operating

  The Q1 operating loss of $3.4M includes the impact of non-cash items including amortisation, depreciation and the impact of share-based compensation expenses. Adjusting for these non-cash items, the Company delivered $9.9M of EBITDA 3 for the quarter. 2  Non-cash items include amortisation of the acquired metreleptin and lomitapide intangible assets ($10.7M), amortisation of the inventory fair value step-up that was acquired at the acquisition date ($1.0M), depreciation and amortisation ($0.3M) and share based compensation expenses ($1.3M). 3  EBITDA is earnings before interest, tax, depreciation, amortisation and share based compensation expenses. To supplement Amryt s financial results presented in accordance with IFRS generally accepted accounting principles, the Company uses EBITDA as a key measure of company performance as the Company believes that this measure is most reflective of the operational profitability or loss of the Company and provides management and inve

Boston
Massachusetts
United-states
Ireland
Canada
Dublin
France
Israel
Joe-wiley
Amryt-pharma
Chiasma-inc
Nasdaq

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.